A Comparison of Rosuvastatin Monotherapy and Rosuvastatin Plus Ezetimibe Combination Therapy in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Autor:	Dadzie SK; Internal Medicine, Piedmont Athens Regional Medical Center, Athens, USA., Tabowei G; Internal Medicine, Texas Tech University Health Sciences Center, Odessa, USA., Kaur M; Hospital Medicine, HCA Florida Capital Hospital, Tallahassee, USA., Ahmed S; Cardiology, Mohtarma Benazir Bhutto Shaheed Medical College, New Mirpur City, PAK., Thakur A; Medicine, Tbilisi State Medical University, Tbilisi, GEO., Khreis K; Pediatrics, University of Pécs Medical School, Pécs, HUN., Bai M; Obstetrics and Gynaecology, Sheikh Zayed Hospital for Women, Larkana, PAK., Amin A; Cardiology, PNS (Pakistan Navy Ship) Shifa Hospital, Karachi, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jun 02; Vol. 16 (6), pp. e61526. Date of Electronic Publication: 2024 Jun 02 (Print Publication: 2024).
DOI:	10.7759/cureus.61526
Abstrakt:	Type 2 diabetes mellitus is a metabolic condition where vascular inflammation and oxidative stress contribute to disease progression and associated complications. Although statins are recommended for managing dyslipidemia in diabetes, additional therapies are often required to achieve target lipid levels. This meta-analysis aimed to evaluate the efficacy of rosuvastatin monotherapy versus combination therapy with ezetimibe in patients with type 2 diabetes. A systematic literature search was conducted across multiple databases until April 2024, identifying six randomized controlled trials meeting the inclusion criteria. The meta-analysis revealed that the rosuvastatin plus ezetimibe combination resulted in significantly greater reductions in total cholesterol (mean difference, or MD: 19.49; 95% CI: 13.99 to 24.99), triglycerides (MD: 13.44; 95% CI: 2.04 to 24.85), and low-density lipoprotein cholesterol (MD: -17.68; 95% CI: 12.85 to 22.51) compared to rosuvastatin monotherapy. Conversely, rosuvastatin monotherapy achieved a greater reduction in HbA1c levels (MD: -0.11; 95% CI: -0.17 to -0.04). Subgroup analysis demonstrated that using the same dose of rosuvastatin in both groups led to more significant improvements in lipid parameters with lower heterogeneity. The findings suggest that the rosuvastatin-ezetimibe combination may be a more effective lipid-lowering strategy for patients with type 2 diabetes, though larger studies are needed to assess long-term safety and optimal dosing. Additionally, while rosuvastatin monotherapy provided modest HbA1c reductions, the clinical relevance remains uncertain, and potential risks with high-dose statins should be considered. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Dadzie et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu